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Abstract
Objective: To compare the efficacy and safety of tofacitinib and baricitinib in patients with RA in a real-world
setting.
Methods: A total of 242 patients with RA who were treated with tofacitinib (n = 161) or baricitinib (n = 81) were
enrolled. We evaluated efficacy and safety between tofacitinib and baricitinib using multivariable analyses to avoid
confounding. Their clinical disease activity and AEs were evaluated for 24 weeks.
Results: The mean (SD) DAS28-ESR change from baseline to 24 weeks was 1.57 (1.55) (tofacitinib) and 1.46 (1.36)
(baricitinib). There was no significant difference in the clinical response between the two groups (adjusted mean
difference, 0.04; 95% CI, −0.35 to 0.28). The efficacy was not significantly changed in the patients without
concomitant MTX use in both groups, but the concomitant MTX use showed better clinical efficacy in the cases of
baricitinib treatment. In both groups, the most common AE was herpes zoster infection, and the AE rates were
similar between the two groups. However, the predictive factors contributing to clinical response as revealed by a
multivariable logistic analysis differed. The concomitant oral steroid use was independently associated with the
achievement of DAS-low disease activity in the tofacitinib group, whereas in the baricitinib group, the number of
biological and/or targeted synthetic DMARDs previously used was associated.
Conclusions: Our findings indicate that tofacitinib and baricitinib had comparable continuing efficacies and safety
profiles. However, there is a possibility that the influence of clinical characteristics on the treatment response differs.
The comparison provides useful information to the optimal use of JAK inhibitors in real-world settings.
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Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by chronic synovitis that symmetric-
ally develops in joints, and persistent inflammation in
joints leads to the destruction of joints and tendons,
resulting in deformities and ankylosis. Rheumatoid arth-
ritis affects approx. 0.5–1% of the population worldwide.
The use of biological disease-modifying antirheumatic
drugs (bDMARDs)—which are able to selectively inter-
fere with a specific molecule such as tumor necrosis
factor-alpha (TNF-α) or a cellular pathway such as T-
cell activation—enables the achievement of low disease
activity or even remission in a high percentage of cases
[1, 2]. In addition to bDMARDs, recently, Janus kinase
(JAK) inhibitors can be used to treat RA and are begin-
ning to play a crucial role in the management of RA [3].
Because the JAK pathway is involved in many biologic
functions (including the activation of the inflammatory
cascade in immune cells) and is associated with several
cytokines that are closely related to the pathogenesis of
RA [4], blockade of the JAK pathway is effective in RA
treatment.
Tofacitinib is a non-selective first-generation JAK
inhibitor that acts by inhibiting JAK1, JAK2, JAK3,
and to a lesser extent TYK2. Six pivotal randomized
phase III clinical studies demonstrated RA patients’
good treatment response to tofacitinib among patients
with differing statuses such as methotrexate (MTX)-
naïve subjects, and the studies revealed the patients’
inadequate response to MTX/bDMARDs [5–10].
Moreover, several studies in real-world settings indi-
cated that tofacitinib was as effective as was observed
in these phase III trials [11, 12].
After the approval of tofacitinib in 2012 (USA) and
2013 (Japan), baricitinib was approved for the treatment
of RA in 2018 (USA) and 2017 (Japan). Baricitinib pre-
vents the activation of JAK1 and JAK2. As with tofaciti-
nib, the clinical efficacy of baricitinib was assessed by
several randomized phase III clinical studies, and these
studies showed the usefulness of baricitinib as a mono-
or combo-therapy for patients with RA [13–16]. Regard-
ing the two drugs’ pharmacological action, baricitinib
acts more selectively on JAK1 than tofacitinib, and for
example, baricitinib thus strongly prevents STAT phos-
phorylation by interleukin (IL)-6 [17]. On the other
hand, tofacitinib acts on JAK3, which baricitinib cannot
inhibit. Considering such differences, the treatment re-
sponse might be different even between these two JAK
inhibitors. However, until now, no published data of a
direct comparison among JAK inhibitors in RA have
been available, and the efficacy and safety of these JAK
inhibitors, especially baricitinib, in a real-world setting
have rarely been described. It is important to determine
the differences and similarities of these JAK inhibitors in
a real-world setting for the treatment of RA so that the
optimal agent can be administered in each case or
population.
Direct comparisons of clinical efficacy among treat-
ments are generally scarce in randomized controlled tri-
als (RCTs), especially in RA treatment. However, by
appropriately controlling confounding, the data from ob-
servational studies can be used for a comparison. We
conducted the present study to compare the efficacy and
safety of tofacitinib with those of baricitinib by compar-
ing multiple variable-adjusted estimates in a real-world
setting. We also analyzed the respective factors that con-




All patients were registered in this study at one of the
following institutions: the Department of Immunology
and Rheumatology, Nagasaki University Graduate School
of Biomedical Sciences; Sasebo Chuo Hospital, Isahaya
General Hospital, Sasebo City General Hospital, and the
Japanese Red Cross Nagasaki Genbaku Hospital. A total
of 242 patients who were treated with tofacitinib (n =
161) between August 2013 and October 2019 or bariciti-
nib (n = 81) between January 2018 and February 2020
were enrolled. All patients had a diagnosis of RA based
on the 2010 American College of Rheumatology (ACR)/
European League against Rheumatism (EULAR) classifi-
cation criteria for RA [18].
We collected the enrolled patients’ data at the initi-
ation of each treatment, including the disease duration,
positivity of rheumatoid factor (RF) and anti-
citrullinated protein antibodies (ACPA), modified Health
Assessment Questionnaire (mHAQ), history of previous
disease-modifying antirheumatic drugs (DMARDs), and
concomitant medications. The treatment with tofacitinib
or baricitinib was administered by the patients’ attending
rheumatologists in accord with the Japan College of
Rheumatology (JCR) guidelines. The patients received ei-
ther 5 mg of tofacitinib twice/once daily (in patients with
renal impairment) daily or 4 mg/2mg (in patients with
renal impairment) of baricitinib once daily with no
change in any concomitant csDMARD therapy during
the 24-week observation period. The patients gave their
informed consent to be subjected to the protocol, which
was approved by the Institutional Review Board of Naga-
saki University (IRB approval no. 11032819).
Clinical efficacy and safety
The patients’ clinical disease activity was assessed using
the Disease Activity Score in 28 joints-erythrocyte sedi-
mentation rate (DAS28-ESR), Simplified Disease Activity
Index (SDAI), and Clinical Disease Activity Index
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(CDAI) at the baseline and at 4, 8, 12, 16, 20, and 24
weeks after the initiation of tofacitinib or baricitinib
treatment. Safety was also assessed based on the adverse
events (AEs) reported by the patients as well as on the
findings of physical examinations until 24 weeks.
Statistical analysis
We summarized and compared the baseline demo-
graphic and disease characteristics between the
baricitinib-treated and tofacitinib-treated patients. The
continuous variables were compared by Wilcoxon’s rank
sum test and are presented as the medians with inter-
quartile range (IQR). The categorical variables were
compared by Fisher’s exact test and are presented as the
number of patients and percentages.
For the evaluation of efficacy, first, we conducted a
mixed effect model with a repeated measures analysis of
variance (ANOVA) to ascertain whether there were sig-
nificant differences in clinical efficacy between the two
treatment groups during the treatment period. The
model included the treatment group, treatment period,
baseline efficacy, and the multiple term of group and
period; confounders included sex, age, disease duration,
MTX use, oral steroid use, the number of previous bio-
logical or/and targeted synthetic (b/ts) DMARD use,
DAS28-ESR, SDAI, mHAQ, presence of RF, and ACPA.
Second, the disease activities during week 24 were evalu-
ated risk, crude risk ratio, and adjusted risk ratio, which
was estimated by the modified Poisson regression model
[19]. The model included the treatment group and
above-mentioned confounders. Here, “risk” refers to a
remission rate or a rate of patients who achieved less
than low disease activity. We used the last observation
carried forward (LOCF) method for patients who with-
drew before week 24 and in cases of missing data. Third,
we summarized the disease activity between groups with
and without MTX treatment by percentage and com-
pared the values with Fisher’s exact test.
For the evaluation of safety and drug retention rate,
we first summarized and compared the adverse events.
We then estimated the drug retention rate in each group
by the Kaplan-Meier method and compared them by the
Cox proportional hazard model, which is the same as
the modified Poisson regression model above.
Finally, we evaluated the predictive factor of clinical
responses by performing univariate and multivariable lo-
gistic regression analyses. Variables with P values < 0.1
in the univariate logistic regression analyses were en-
tered in the multivariable logistic regression analysis.
The statistical significance for all tests was defined by a
two-tailed P value < 0.05. We calculated a 95% confi-
dence interval (95% CI) for each estimate. Analyses were
performed using R ver. 4.0.2 (R Foundation for Statis-
tical Computing, Vienna, Austria), GraphPad Prism
software (GraphPad Software, San Diego, CA), and JMP
Statistical Software (SAS Institute, Cary, NC).
Results
Baseline characteristics
The patients’ baseline demographic and disease charac-
teristics are summarized in Table 1. The tofacitinib-
treated patients had worse disease activity scores, longer
disease durations, more concomitant use of MTX, and
lower RF positivity compared to the baricitinib-treated
patients. However, the difference was significant only in
the rate of a concomitant use of MTX. The patients
treated with tofacitinib exhibited high-moderate disease
activity (DAS28-ESR 5.17, SDAI 20, CDAI 19) with a
median age of 67 years and median disease duration of
12 years. The patients treated with baricitinib also exhib-
ited high-moderate disease activity (DAS28-ESR 5.13,
SDAI 19, CDAI 18) with a median age of 66 years and
median disease duration of 11 years. The concomitant
use of MTX at baseline was present in 68% of the tofaci-
tinib group and 47% of the baricitinib group. The con-
comitant use of an oral steroid was present in 53% of
the tofacitinib group and 47% of the baricitinib group.
Approximately 80% of the patients in both groups had
been treated with a b/ts DMARD (the median number
of previous uses of b/tsDMARDs was 2 in both groups).
Regarding switching from another JAK inhibitor, none
of the patients in the tofacitinib group had been treated
with another JAK inhibitor, whereas 26 of the patients in
the baricitinib group had been treated with tofacitinib.
Clinical efficacy
Figure 1 illustrates the changes in the DAS28-ESR values
over the 24-week study period. The mean (standard de-
viation (SD)) DAS28-ESR score for the tofacitinib-
treated patients decreased significantly from 5.16 (1.42)
at baseline to 3. 29 (1.08) at 24 weeks; the mean (SD) of
change from baseline to 24 weeks was 1.57 (1.54). The
baricitinib-treated patients also showed a significantly
improved DAS28-ESR from 5.01 (1.37) at baseline to 3.
57 (1.47) at 24 weeks; the mean (SD) of change from
baseline to 24 weeks was 1.46 (1.36). The adjusted differ-
ence mean at 24 weeks between tofacitinib and bariciti-
nib was −0.04 (95% CI, −0.35 to 0.28). At the 24-week
follow-up, the DAS28-ESR, SDAI, and CDAI remission
rates were 18.0%, 21.1%, and 18.0% in the tofacitinib
group and 24.7%, 27.2%, and 22.2% in the baricitinib
group, respectively. The rates of patients who achieved
less than low disease activity of each clinical indicator
(DAS28-ESR, SDAI, CDAI) were 31.7%, 64.0%, and
65.8% in the tofacitinib-treated group and 45.7%, 61.7%,
and 60.5% in the baricitinib-treated group (Table 2). Ad-
justed remission rate also showed the same pattern.
There was no significant difference in the clinical
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responses of the baricitinib-treated patients and the
tofacitinib-treated patients. These results suggest that
the efficacy of tofacitinib for RA over a 24-week period
and that of baricitinib were similar in daily clinical
practice.
We next analyzed the efficacy of each of the JAK in-
hibitors in subgroups divided by the patients’ concomi-
tant use/non-use of MTX. Although age and mHAQ in
both groups, disease duration, and history of b/ts DMAR
D use in the tofacitinib group were different, the
baseline variables including disease activity of the sub-
groups were almost equal regardless of MTX use/non-
use (Suppl. Table S1). In the tofacitinib group, the mean
DAS28-ESR change from baseline to 24 weeks was 1.42
in the patients with concomitant use of MTX and 1.07
in those without concomitant use of MTX, whereas in
the baricitinib group, the corresponding values were
1.47 and 0.89, respectively.
The proportions of disease activity at 24 weeks defined
by the DAS28-ESR are shown in Fig. 2. There were no
Table 1 Clinical characteristics of the study population
Tofacitinib (n = 161) Baricitinib (n = 81) P value
Female, n (%) 133 (82.6) 68 (84.0) 0.857
Age (years) 67 [58–73] 66 [56–74] 0.667
Duration of RA (years) 12 [6–18] 11 [4–18] 0.243
Concomitant MTX use, n (%) 109 (67.7) 37 (45.7) 0.001
Mean MTX dose (mg/week) 8.62 ± 2.49 8.05 ± 2.69 0.427
Concomitant oral steroid use, n (%) 86 (53.4) 38 (46.9) 0.345
Mean oral steroid dose (mg/day) 4.80 ± 2.72 4.80 ± 3.08 0.844
ACPA positive, n (%) 124 (77.0) 65 (80.2) 0.624
RF positive, n (%) 122 (75.8) 70 (86.4) 0.064
No prior use of b/tsDMARDs, n (%) 37 (23.0) 18 (22.2) > 0.999
Number of previous use of b/tsDMARDs 2.00 [1.00–3.00] 2.00 [1.00–3.00] 0.968
DAS28-ESR 5.17 [4.08–6.11] 5.13 [4.21–5.98] 0.622
SDAI 20 [14–32] 19 [14–29] 0.507
CDAI 19 [12–30] 18 [12–27] 0.497
mHAQ 0.60 [0.1–1.3] 0.62 [0.12–1.38] 0.372
Data are median [interquartile range] unless otherwise indicated
RA rheumatoid arthritis, MTX methotrexate, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor, b/tsDMARDs biological and/or targeted synthetic
disease-modifying antirheumatic drugs, DAS disease activity score, ESR erythrocyte sedimentation rate, SDAI Simplified Disease Activity Index, CDAI Clinical Disease
Activity Index, mHAQ modified Health Assessment Questionnaire
Fig. 1 Time course of disease activity scores over 24 weeks of tofacitinib and baricitinib treatments. Points and bars represent means and
standard deviations, respectively. *,†P < 0.0001 vs baseline by the Wilcoxon signed rank test. ESR erythrocyte sedimentation rate, DAS disease
activity score
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significant differences in the above indices between the
patients with and without concomitant use of MTX in
both groups.
Drug retention and adverse events
There was no significant difference in the drug retention
rate between the tofacitinib and baricitinib groups (ad-
justed hazard ratio for discontinuation,1.43; 95% CI, 0.76
to 2.67, tofacitinib vs baricitinib). The corresponding
Kaplan-Meier plots of discontinuation are illustrated in
Fig. 3. During the 24-week follow-up period, 38 patients
(23.6%) were discontinued tofacitinib treatment and 15
patients (18.5%) were discontinued baricitinib treatment.
The reasons for discontinuation were as follows. In the
tofacitinib group, lack of efficacy (n = 17), request of the
patient (n = 3), and an AE (pneumonia [n = 4], herpes
zoster [n = 2], fungus infection, skin cancer, colon can-
cer, lung cancer, nausea [n = 4], interstitial pneumonia,
vertigo, diarrhea, and hair loss) (n = 18) were the rea-
sons. In the baricitinib group, lack of efficacy (n = 10)
and an AE (pneumonia, herpes zoster, breast cancer,
headache, and elevation of creatine kinase) (n = 5) were
the reasons.
Table 3 summarizes the AEs experienced by the 32 pa-
tients in the tofacitinib group and the 14 patients in the
baricitinib group. The incidence rate of AEs was not
Table 2 Disease activity at 24 weeks
Tofacitinib (n = 161) Baricitinib (n = 81) Crude risk ratio (95% CI) Adjusted risk ratio (95% CI)
DAS28-ESR
Remission, n (%) 29 (18.0) 20 (24.7) 0.73 (0.44 to 1.21) 0.71 (0.44 to 1.18)
LDA achievement, n (%) 51 (31.7) 37 (45.7) 0.69 (0.50 to 0.96) 0.68 (0.49 to 0.95)
SDAI
Remission, n (%) 34 (21.1) 22 (27.2) 0.78 (0.49 to 1.24) 0.73 (0.46 to 1.16)
LDA achievement, n (%) 103 (64.0) 50 (61.7) 1.04 (0.84 to 1.27) 1.03 (0.85 to 1.24)
CDAI
Remission, n (%) 29 (18.0) 18 (22.2) 0.81 (0.48 to 1.37) 0.80 (0.47 to 1.37)
LDA achievement, n (%) 106 (65.8) 49 (60.5) 1.09 (0.88 to 1.34) 1.11 (0.91 to 1.35)
Adjusted risk ratios were estimated using a modified Poisson regression model, which included the treatment group (tofacitinib vs baricitinib) and confounders as
sex, age, disease duration, MTX use, oral steroid use, the number of previous biological/target synthetic DMARD use, DAS28-ESR, SDAI, mHAQ, presence of RF,
and ACPA
DAS disease activity score, ESR erythrocyte sedimentation rate, LDA low disease activity, SDAI Simplified Disease Activity Index, CDAI Clinical Disease Activity Index,
CI confidence interval
Fig. 2 a The proportion of disease activity at 24 weeks after the initiation of tofacitinib treatment with or without a concomitant use of MTX. b
The proportion of disease activity at 24 weeks after the initiation of baricitinib treatment with or without a concomitant use of MTX. Disease
activity was categorized as follows. DAS 28-ESR < 2.6 (remission), 2.6 to < 3.2 (LDA), 3.2–5.1 (MDA), > 5.1 (HDA). MTX methotrexate, LOCF last
observation carried forward, ESR erythrocyte sedimentation rate, DAS disease activity score, LDA low disease activity, MDA moderate disease
activity, HDA high disease activity
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significantly different between the groups. The most
common AE was infection (12.4% in the tofacitinib
group, 13.6% in the baricitinib group). Among the infec-
tions, as expected, herpes zoster infection was the most
frequent in both groups (5.6% in the tofacitinib group,
4.9% in the baricitinib group). Few neoplasms were seen
in each group (3 in the tofacitinib group, 1 in the barici-
tinib group) during 24 weeks. The rate of herpes zoster
was slightly higher in the tofacitinib group, and the dif-
ference was not significant. Moreover, the rates of other
Fig. 3 Estimated cumulative incidence of the discontinuation of tofacitinib and baricitinib treatment during the 24-week treatment period
Table 3 Adverse events
Tofacitinib (n = 161) Baricitinib (n = 81) P value
All Events, n (%) 32 (19.9) 17 (21.0) 0.866
Infection 20 (12.4) 11 (13.6) 0.840
Herpes zoster 9 (5.6) 4 (4.9)
Pneumonia 6 (3.7) 1 (1.2)
Upper respiratory infection 4 (2.5) 3 (3.7)
Callus infection 1 (1.2)
Cytomegalovirus infection 1 (1.2)
Fungus infection 1 (0.6)
Sepsis 1 (1.2)
Gastrointestinal disorder 6 (3.7) 2 (2.5) 0.720
Gastric ulcer 1 (1.2)
Nausea 4 (2.5) 1 (1.2)
Diarrhea 2 (1.2)
Neoplasm 3 (1.9) 1 (1.2) > 0.999
Breast cancer 1 (1.2)
Colon cancer 1 (0.6)
Skin cancer 1 (0.6)
Lung cancer 1 (0.6)
Others 3 (1.9) 3 (3.7) 0.405
Hair loss 1 (0.6)
Vertigo 1 (0.6) 1 (1.2)
Headache 1 (1.2)
Interstitial pneumonia 1 (0.6)
Elevation of creatine kinase 1 (1.2)
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AEs such as infection and gastrointestinal disorder were
also similar in each subgroup of the treatment groups.
Comparison of factors contributing to a good clinical
response between tofacitinib and baricitinib treatment
We next investigated the factors that contribute to the
clinical responses to baricitinib and tofacitinib. The
baseline characteristics that predict the achievement of
DAS28-ESR-low disease activity (LDA) in the univariate
analysis were as follows (Table 4): in the tofacitinib
group, the concomitant use of oral steroid, the DAS28-
ESR at the time of treatment initiation, and the value of
mHAQ; in the baricitinib group, the concomitant use of
an oral steroid, the number of b/tsDMARDs previously
used, the DAS28-ESR at the time of treatment initiation,
and the value of mHAQ. Among these factors, the re-
sults of the multivariable logistic analysis demonstrated
that the concomitant use of an oral steroid was inde-
pendently associated with the achievement of DAS-LDA
in the tofacitinib group, whereas, in the baricitinib
group, the multivariable analysis identified the significant
association between the association of DAS28-ESR-LDA
achievement and the number of b/tsDMARDs previously
used, and the DAS-ESR at the time of treatment
initiation.
Discussion
If superiority or inferiority exists among tsDMARDs, it
is very important to determine this information for the
algorithm of RA treatment. Knowledge of the baseline
variables that influence the treatment response to each
tsDMARD is also useful information when selecting a
tsDMARD toward the goal of achieving better clinical
outcomes, because in RA, many factors affect the treat-
ment responses. For example, patients with shorter dis-
ease durations have shown better clinical outcomes with
biological DMARDs compared to those with longer dis-
ease durations [20], and the serological status concern-
ing autoimmune antibodies (RF and ACPA) is not only a
prognostic factor but also a factor in treatment re-
sponses [21, 22]. Unfortunately, no head-to-head RCTs
testing JAK inhibitors are available. In the present study,
we compared the effectiveness and safety of two JAK in-
hibitors used to treat RA using multivariable analyses to
avoid confounding. The findings obtained with our
follow-up cohort in real medical practice demonstrated
that tofacitinib and baricitinib had comparable efficacies
and similar safety profiles but differences in the predict-
ive factors that contribute to their treatment responses.
Our analyses revealed that 31.7% of the tofacitinib-
treated group and 45.7% of the baricitinib-treated group
achieved low disease activity as defined by the DAS28-
Table 4 Independent predictors for the achievement of LDA at 24 weeks in multivariable analysis
Tofacitinib Baricitinib
Variables Univariate model Multivariable model Univariate model Multivariable model
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value





















0.050 0.339 (0.102–1.129) 0.073






0.005* 0.700 (0.504–0.971) 0.026*











< 0.001* 0.395 (0.225–0.694) < 0.001*






< 0.001* 0.697 (0.301–1.611) 0.396










OR odds ratio, 95% CI 95% confidence interval, MTX methotrexate, b/tsDMARDs biological and/or targeted synthetic disease-modifying antirheumatic drugs, JAK
Janus kinase, DAS disease activity score, mHAQ modified Health Assessment Questionnaire, ESR erythrocyte sedimentation rate, ACPA anti-citrullinated protein
antibodies, RF rheumatoid factor
*P < 0.05
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ESR at 24 weeks, with no significant between-group dif-
ference. This result indicated that the two JAK inhibitors
are effective and comparable in the daily clinical practice
of treating RA patients who have various characteristics
and treatment histories. Such a variety of clinical charac-
teristics is different from the cohorts in most RCTs and
thus has not been elucidated in RCTs.
It is crucial in RA treatment to know whether the effi-
cacy of a drug depends on the concomitant use of MTX
or not. In the present population, the tofacitinib and
baricitinib treatments were effective even in patients
without concomitant use of MTX. In those patients, the
rates of LDA achievement were 30.8% in the tofacitinib
group and 40.9% in the baricitinib group. These results
are consistent with those of two phase III trials in which
tofacitinib monotherapy and baricitinib monotherapy
provided good clinical responses; the ACR 20/50/70 re-
sponses were 59.8/31.1/15.4 and 76.7/59.7/42.1, respect-
ively [5, 13]. Moreover, based on those results, the 2019
EULAR recommendation for the management of RA
stated that in patients who cannot use csDMARDs as
comedication, IL-6 pathway inhibitors and tsDMARDs
may have some advantages compared to other
bDMARDs [3].
However, in our present investigation, although the
difference was not significant, the patients with con-
comitant use of MTX showed better clinical efficacy
compared to those without concomitant use of MTX
in both the tofacitinib and baricitinib groups. The Δ
(ΔDAS28-ESR from at baseline to at 24 weeks) values
from the concomitant use of MTX to without the
concomitant use of MTX were 0.35 in the tofacitinib
group and 0.58 in the baricitinib group. And, our re-
sults also suggested that baricitinib treatment has
more advantages in MTX-comedication therapy for
the reduction of the DAS28-ESR score compared to
tofacitinib treatment. The efficacy of concomitant
therapy with MTX might be different for each JAK
inhibitor. This point should be verified in studies with
larger numbers of patients.
There was no significant difference in the retention
rate between the present baricitinib and tofacitinib
groups, as ~ about 80% of the patients continued
treatment in both groups. These retention rates are
comparable to those of the bDMARDs for which data
were acquired from daily clinical practice [23–25]. In
the present study, most of the instances of treatment
discontinuation occurred before 12 weeks, and lack of
efficacy was the most common discontinuation reason
in both groups. This might reflect a treat-to-target
strategy even in JAK inhibitor treatment, namely,
“until the desired treatment target is reached, drug
therapy should be adjusted at least every three
months.” [26].
Adverse events occurred in 19.9% of the tofacitinib
group and 21.0% of the baricitinib group in this study.
As with other RCTs, herpes zoster infections were the
most frequent AE (5.6% in the tofacitinib group and
4.9% in the baricitinib group). The incidence of herpes
zoster infection was higher in the tofacitinib group, and
this tendency has also been observed in RCTs. In an in-
tegrated analysis of RCTs and long-term extension stud-
ies, the incidence per 100 patient-years of herpes zoster
was 4.0 in tofacitinib treatment and 3.3 in baricitinib
treatment [27, 28]. Although the between-group differ-
ence in the herpes zoster infections in our study was not
significant and the results of the integrated analysis can-
not be compared directly because the patient back-
grounds differ, we speculate that this difference might
arise from the different selectivity for inhibition of the
JAK pathway. Larger and longer-term studies are needed
to examine this topic.
Interestingly, we observed that the predictors of treat-
ment response differed by the type of JAK inhibitor. The
concomitant use of an oral steroid was associated with
the achievement of DAS-LDA in tofacitinib groups,
whereas the number of b/tsDMARDs previously used
was a significant factor only in the baricitinib group. The
concomitant use of an oral steroid did not enhance the
efficacy of the JAK inhibitors but decreased the efficacy
of tofacitinib at 24 weeks. Considering this result and the
potential harmful effects of oral steroids, the concomi-
tant use of an oral steroid is not necessary for the treat-
ment of RA using JAK inhibitors, and we should use the
lowest possible dose of oral steroids for the shortest time
as in the EULAR recommendation [3]. The result that
the number of b/tsDMARDs previously used was associ-
ated with treatment response in the baricitinib group is
consistent with another study in a real-world setting.
Guideli et al. reported that the drug survival of bariciti-
nib is higher in bDMARD-naïve patients [29]. Consider-
ing these results, the initiation of baricitinib at an earlier
phase of RA might be better. To determine the optimal
use of different JAK inhibitors in daily clinical practice,
further analyses of predictors in real-world settings are
necessary.
The treatment response to the JAK inhibitors among
the patients who showed an inadequate response to an-
other JAK inhibitor is also required information for the
optimal use of JAK inhibitors. In the present baricitinib-
treated group, 26 patients had been treated with tofaciti-
nib. Although the multivariable analysis revealed no rela-
tionship between inadequate response to tofacitinib and
the patients’ achievement of DAS28-ESR-LDA, the mean
DAS28-ESR change from baseline to 24 weeks in the
tofacitinib-treated patients was lower than that in the
non-tofacitinib-treated patients (0.91, 1.27, respectively,
P = 0.628). This result suggested the possibility of
Iwamoto et al. Arthritis Research & Therapy          (2021) 23:197 Page 8 of 10
decreased efficacy of JAK inhibitors in the patients with
inadequate response to another JAK inhibitor.
Limitations of this study are its small sample size
and short observation period. In particular, the statis-
tical reliability of the multivariable analysis that we
performed in this study was not very strong because
of the small samples. In addition, the study was car-
ried out in a routine clinical practice situation, and
we thus could not conduct a statistical power analysis
about the sample numbers required for comparison
before the study. We attempted to control for con-
founding using all available information and com-
pared the efficacy and safety of JAK inhibitors.
However, a perfect causal structure cannot be identi-
fied, and some confounders remain unmeasured;
hence, residual confounding is not avoidable. In
addition, we did not examine the effects on patient-
reported outcomes (PROs) such as with the 36-item
Short Form Health Survey (SF-36). The importance of
PROs in RA management has been highlighted in
order to reflect the patients’ satisfaction with their
treatment and their role in making treatment deci-
sions. Furthermore, the administration route of JAK
inhibitors is oral, not a subcutaneous/intravenous in-
jection. And, based on their regulation of multiple cy-
tokines, JAK inhibitors have been thought to reduce
pain in particular among the symptoms of RA [30–
32]. The patients who are treated with JAK inhibitors
might thus be satisfied with their treatments. We will
analyze PROs in a future study.
Conclusions
In conclusion, our findings demonstrated that tofacitinib
and baricitinib had comparable continuing efficacies and
safety profiles. The efficacy of the two drugs was almost
the same even without the concomitant use of MTX. A
lesser use of previous b/tsDMARDs contributed to the
clinical response to baricitinib but not to tofacitinib.
Comparisons performed with adjusting confounding can
provide important and useful information about the
optimal use of JAK inhibitors in the management of RA
in real-world settings.
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